Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma

@article{Wakao2001SerumTK,
  title={Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma},
  author={Daisuke Wakao and Ikuo Murohashi and K Tominaga and Katsuhiko Yoshida and Kuniya Kishimoto and Fumiharu Yagasaki and Yukashi Itoh and Kazuko Itoh and Takashi Sakata and Noriysau Kawai and Hiroyuki Kayano and Toshio Suzuki and Akira Matsuda and Kanji Hirashima and Masami Bessho},
  journal={Annals of Hematology},
  year={2001},
  volume={81},
  pages={140-146}
}
Before and after therapy, serum thymidine kinase (TK) and soluble interleukin-2 receptor (sIL-2R) were serially determined in 28 patients with malignant lymphoma (ML). In 15 patients achieving and maintaining complete remission (CR) for more than 2 years, serum TK and sIL-2R were unchanged or decreased gradually. In contrast, logarithmic linear increases of TK and sIL-2R were observed in 13 relapsed patients. The increments of the serum markers occurred more than 10 months before the relapse. A… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

rum β 2 - microglobulin and serum thymidine kinase are independent predictors of progression - free survival in chronic lymphocytic leukemia and immunocytoma

S Rehn, B Glimelius, C Sundstrom
Leuk Lymphoma • 1996

Biologic and pharmacologic basis of cancer chemotherapy

RT Skeel, NA Lachant
Hand book of cancer chemotherapy • 1995

A predictive model for aggressive non-Hodgkin's lymphoma.

The New England journal of medicine • 1993

Similar Papers

Loading similar papers…